RnR Market Research Offers “Skin And Skin Structure Infections (SSSI) – PipelineReview, H1 2013” Report at US$ 2000 (Singl...
List of Figures 6Introduction 7Global Markets Direct Report Coverage 7Skin And Skin Structure Infections (SSSI) Overview 8...
ceftaroline fosamil - Drug Profile 45Product Description 45Mechanism of Action 45R&D Progress 45omadacycline tosylate - Dr...
avarofloxacin - Drug Profile 71Product Description 71Mechanism of Action 71R&D Progress 71ABI-0043 - Drug Profile 73Produc...
Disclaimer 116List of TablesNumber of Products Under Development for Skin And Skin Structure Infections (SSSI), H1 2013 9P...
Upcoming SlideShare
Loading in...5
×

Skin And Skin Structure Infections Pipeline Review H1 2013

137

Published on

Buy the report "Skin And Skin Structure Infections (SSSI) – Pipeline Review, H1 2013" at US $2000 for a Single User PDF License from RnR Market Research Reports Library.

Published in: Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
137
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
1
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Skin And Skin Structure Infections Pipeline Review H1 2013

  1. 1. RnR Market Research Offers “Skin And Skin Structure Infections (SSSI) – PipelineReview, H1 2013” Report at US$ 2000 (Single User License). The report got published inFeb 2013.Global Markets Direct’s, ‘Skin And Skin Structure Infections (SSSI) – Pipeline Review, H1 2013′, providesan overview of the indication’s therapeutic pipeline. This report provides information on the therapeuticdevelopment for Skin And Skin Structure Infections (SSSI), complete with latest updates, and specialfeatures on late-stage and discontinued projects. It also reviews key players involved in the therapeuticdevelopment for Skin And Skin Structure Infections (SSSI). Skin And Skin Structure Infections (SSSI) –Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’sproprietary databases, Company/University websites, SEC filings, investor presentations and featuredpress releases from company/university sites and industry-specific third party sources, put together byGlobal Markets Direct’s team.Get a Report Copy @ http://www.rnrmarketresearch.com/skin-and-skin-structure-infections-sssi-pipeline-review-h1-2013-market-report.htmlScope- A snapshot of the global therapeutic scenario for Skin And Skin Structure Infections (SSSI).- A review of the Skin And Skin Structure Infections (SSSI) products under development by companiesand universities/research institutes based on information derived from company and industry-specificsources.- Coverage of products based on various stages of development ranging from discovery till registrationstages.- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.- Coverage of the Skin And Skin Structure Infections (SSSI) pipeline on the basis of route ofadministration and molecule type.- Key discontinued pipeline projects.- Latest news and deals relating to the products.Reasons to buy- Identify and understand important and diverse types of therapeutics under development for Skin AndSkin Structure Infections (SSSI).- Identify emerging players with potentially strong product portfolio and design effective counter-strategiesto gain competitive advantage.- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.- Devise corrective measures for pipeline projects by understanding Skin And Skin Structure Infections(SSSI) pipeline depth and focus of Indication therapeutics.- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with themost attractive projects to enhance and expand business potential and scope.- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors thatdrove them from pipeline.Table of ContentTable of Contents 2List of Tables 5
  2. 2. List of Figures 6Introduction 7Global Markets Direct Report Coverage 7Skin And Skin Structure Infections (SSSI) Overview 8Therapeutics Development 9An Overview of Pipeline Products for Skin And Skin Structure Infections (SSSI) 9Skin And Skin Structure Infections (SSSI) Therapeutics under Development by Companies 11Late Stage Products 14Comparative Analysis 14Mid Clinical Stage Products 15Comparative Analysis 15Early Clinical Stage Products 16Comparative Analysis 16Pre-Clinical Stage Products 17Comparative Analysis 17Skin And Skin Structure Infections (SSSI) Therapeutics - Products under Development by Companies 18Companies Involved in Skin And Skin Structure Infections (SSSI) Therapeutics Development 20GlaxoSmithKline plc 20Takeda Pharmaceutical Company Limited 21Rib-X Pharmaceuticals, Inc. 22Paratek Pharmaceuticals, Inc. 23Affinium Pharmaceuticals, Inc. 24Basilea Pharmaceutica Ltd. 25CrystalGenomics, Inc. 26PolyMedix, Inc. 27Bharat Biotech International Limited 28Nabriva Therapeutics AG 29Cempra Pharmaceuticals, Inc. 30Trius Therapeutics, Inc. 31Tetraphase Pharmaceuticals Inc. 32Durata Therapeutics Inc. 33Skin And Skin Structure Infections (SSSI) - Therapeutics Assessment 34Assessment by Monotherapy Products 34Assessment by Route of Administration 35Assessment by Molecule Type 37Drug Profiles 39dalbavancin - Drug Profile 39Product Description 39Mechanism of Action 39R&D Progress 39GSK-1322322 - Drug Profile 41Product Description 41Mechanism of Action 41R&D Progress 41AFN-1252 - Drug Profile 42Product Description 42Mechanism of Action 42R&D Progress 42lysostaphin - Drug Profile 44Product Description 44Mechanism of Action 44R&D Progress 44
  3. 3. ceftaroline fosamil - Drug Profile 45Product Description 45Mechanism of Action 45R&D Progress 45omadacycline tosylate - Drug Profile 47Product Description 47Mechanism of Action 47R&D Progress 47brilacidin - Drug Profile 50Product Description 50Mechanism of Action 50R&D Progress 50BC-3781 - Drug Profile 52Product Description 52Mechanism of Action 52R&D Progress 52BC-7013 - Drug Profile 54Product Description 54Mechanism of Action 54R&D Progress 54delafloxacin - Drug Profile 55Product Description 55Mechanism of Action 55R&D Progress 55radezolid - Drug Profile 58Product Description 58Mechanism of Action 58R&D Progress 58radezolid - Drug Profile 60Product Description 60Mechanism of Action 60R&D Progress 60CG-400549 - Drug Profile 62Product Description 62Mechanism of Action 62R&D Progress 62oritavancin disphosphate - Drug Profile 63Product Description 63Mechanism of Action 63R&D Progress 63fusidic acid - Drug Profile 65Product Description 65Mechanism of Action 65R&D Progress 65tedizolid phosphate - Drug Profile 67Product Description 67Mechanism of Action 67R&D Progress 67faropenem medoxomil - Drug Profile 69Product Description 69Mechanism of Action 69R&D Progress 69
  4. 4. avarofloxacin - Drug Profile 71Product Description 71Mechanism of Action 71R&D Progress 71ABI-0043 - Drug Profile 73Product Description 73Mechanism of Action 73R&D Progress 73eravacycline - Drug Profile 74Product Description 74Mechanism of Action 74R&D Progress 74ceftobiprole medocaril - Drug Profile 75Product Description 75Mechanism of Action 75R&D Progress 75CF-301 - Drug Profile 78Product Description 78Mechanism of Action 78R&D Progress 78Bismith-Thiol Compund For Acute Wound Infection - Drug Profile 79Product Description 79Mechanism of Action 79R&D Progress 79Skin And Skin Structure Infections (SSSI) Therapeutics - Drug Profile Updates 80Skin And Skin Structure Infections (SSSI) Therapeutics - Discontinued Products 105Skin And Skin Structure Infections (SSSI) Therapeutics - Dormant Products 106Skin And Skin Structure Infections (SSSI) - Product Development Milestones 107Featured News & Press Releases 107Nov 16, 2012: PolyMedix Announces Successful Meeting With FDA For Brilacidin 107Oct 25, 2012: Durata Therapeutics Completes Target Enrollment In Phase III Study ComparingDalbavancin To Vancomycin And Linezolid In ABSSSI Patients 107Oct 19, 2012: Trius Presents Clinical Data On Antibiotic Drug Candidate Tedizolid At IDWeek 2012 108Oct 18, 2012: Durata Therapeutics Presents Results From Skin Lesion Measurement Study OfDalbavancin At IDWeek 2012 108Oct 16, 2012: Trius Therapeutics To Present Data From Tedizolid Clinical Studies At IDWeek Conference109Oct 10, 2012: Rib-X Pharma Receives Qualified Infectious Disease Product Designation From FDA ForRadezolid 110Oct 04, 2012: Durata Therapeutics To Present Two Abstracts Concerning Dalbavancin At IDWeek 2012111Sep 17, 2012: Rib-X Pharma Receives Qualified Infectious Disease Product Designation From FDA ForDelafloxacin 111Sep 11, 2012: Durata Therapeutics Announces Completion Of QT Study Of Dalbavancin 112Sep 11, 2012: Rib-X Pharma Presents Data From Multiple Radezolid Studies At ICAAC 2012 113Appendix 115Methodology 115Coverage 115Secondary Research 115Primary Research 115Expert Panel Validation 115Contact Us 116
  5. 5. Disclaimer 116List of TablesNumber of Products Under Development for Skin And Skin Structure Infections (SSSI), H1 2013 9Products under Development for Skin And Skin Structure Infections (SSSI) - Comparative Analysis, H12013 10Number of Products under Development by Companies, H1 2013 12Number of Products under Development by Companies, H1 2013 (Contd..1) 13Comparative Analysis by Late Stage Development, H1 2013 14Comparative Analysis by Mid Clinical Stage Development, H1 2013 15Comparative Analysis by Early Clinical Stage Development, H1 2013 16Comparative Analysis by Pre-Clinical Stage Development, H1 2013 17Products under Development by Companies, H1 2013 18Products under Development by Companies, H1 2013 (Contd..1) 19GlaxoSmithKline plc, H1 2013 20Takeda Pharmaceutical Company Limited, H1 2013 21Rib-X Pharmaceuticals, Inc., H1 2013 22Paratek Pharmaceuticals, Inc., H1 2013 23Affinium Pharmaceuticals, Inc., H1 2013 24Basilea Pharmaceutica Ltd., H1 2013 25CrystalGenomics, Inc., H1 2013 26PolyMedix, Inc., H1 2013 27Bharat Biotech International Limited, H1 2013 28Nabriva Therapeutics AG, H1 2013 29Cempra Pharmaceuticals, Inc., H1 2013 30Trius Therapeutics, Inc., H1 2013 31Tetraphase Pharmaceuticals Inc., H1 2013 32Durata Therapeutics Inc., H1 2013 33Assessment by Monotherapy Products, H1 2013 34Assessment by Stage and Route of Administration, H1 2013 36Assessment by Stage and Molecule Type, H1 2013 38Skin And Skin Structure Infections (SSSI) Therapeutics - Drug Profile Updates 80Skin And Skin Structure Infections (SSSI) Therapeutics - Discontinued Products 105Skin And Skin Structure Infections (SSSI) Therapeutics - Dormant Products 106List of FiguresNumber of Products under Development for Skin And Skin Structure Infections (SSSI), H1 2013 9Products under Development for Skin And Skin Structure Infections (SSSI) - Comparative Analysis, H12013 10Products under Development by Companies, H1 2013 11Late Stage Products, H1 2013 14Mid Clinical Stage Products, H1 2013 15Early Clinical Stage Products, H1 2013 16Pre-Clinical Stage Products, H1 2013 17For more details contact Mr. Priyank Tiwari: sales@rnrmarketresearch.com / +18883915441Website: http://www.rnrmarketresearch.com/

×